Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group.
Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J, Agarwal K, Sabin C, Mutimer D, Moss P, Irving WL, Barnes E; Hepatitis C Trust, UK. Bradshaw D, et al. Among authors: irving wl. J Infect. 2019 Dec;79(6):503-512. doi: 10.1016/j.jinf.2019.10.007. Epub 2019 Oct 16. J Infect. 2019. PMID: 31629015 Free article. Review.
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study.
Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D, Murray-Lyon L, Irving WL, Goldin RD, Foster GR; UK Amantadine Study Group. Caronia S, et al. Among authors: irving wl. J Hepatol. 2001 Oct;35(4):512-6. doi: 10.1016/s0168-8278(01)00140-4. J Hepatol. 2001. PMID: 11682036 Clinical Trial.
Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection.
Brant LJ, Hurrelle M, Balogun MA, Klapper P, Ahmad F, Boxall E, Hale A, Hollyoak V, Ibrahim IB, Irving W, Meigh R, Mutton KJ, Patel BC, Paver WK, Pugh S, Taylor C, Turner AJ, Ramsay ME. Brant LJ, et al. Epidemiol Infect. 2007 Apr;135(3):417-26. doi: 10.1017/S0950268806006832. Epub 2006 Jul 13. Epidemiol Infect. 2007. PMID: 16836798 Free PMC article.
'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.
Bucci C, von Delft A, Christian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. Bucci C, et al. J Gen Virol. 2013 Jun;94(Pt 6):1259-1265. doi: 10.1099/vir.0.051052-0. Epub 2013 Mar 13. J Gen Virol. 2013. PMID: 23486666
Predictors of hepatitis C treatment response: what's new?
Berry L, Irving W. Berry L, et al. Expert Rev Anti Infect Ther. 2014 Feb;12(2):183-91. doi: 10.1586/14787210.2014.874283. Epub 2014 Jan 3. Expert Rev Anti Infect Ther. 2014. PMID: 24404996 Review.
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, Diels J, Lawson A, Neal KR, Wiselka MJ, Ito T, Irving WL. Backx M, et al. Among authors: irving wl. J Viral Hepat. 2014 Mar;21(3):208-15. doi: 10.1111/jvh.12132. Epub 2013 Aug 1. J Viral Hepat. 2014. PMID: 24438682
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. Martin NK, et al. J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338. Epub 2014 Oct 7. J Viral Hepat. 2015. PMID: 25288193 Free PMC article.
235 results